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Excess portal venous long-chain fatty acids induce syndrome
X via HPA axis and sympathetic activation. Am J Physiol
Endocrinol Metab 279: E1286–E1293, 2000.—We tested the
hypothesis that excessive portal venous supply of long-chain
fatty acids to the liver contributes to the development of
insulin resistance via activation of the hypothalamus-pitu-
itary-adrenal axis (HPA axis) and sympathetic system. Rats
received an intraportal infusion of the long-chain fatty acid
oleate (150 nmol/min, 24 h), the medium-chain fatty acid
caprylate, or the solvent. Corticosterone (Cort) and norepi-
nephrine (NE) were measured as indexes for HPA axis and
sympathetic activity, respectively. Insulin sensitivity was
assessed by means of an intravenous glucose tolerance test
(IVGTT). Oleate infusion induced increases in plasma Cort
(D 5 13.5 6 3.6 mg/dl; P , 0.05) and NE (D 5 235 6 76 ng/l;
P , 0.05), whereas caprylate and solvent had no effect. The
area under the insulin response curve to the IVGTT was
larger in the oleate-treated group than in the caprylate and
solvent groups (area 5 220 6 35 vs. 112 6 13 and 106 6 8,
respectively, P , 0.05). The area under the glucose response
curves was comparable [area 5 121 6 13 (oleate) vs. 135 6 20
(caprylate) and 96 6 11 (solvent)]. The results are consistent
with the concept that increased portal free fatty acid is
involved in the induction of visceral obesity-related insulin
resistance via activation of the HPA axis and sympathetic
system.
insulin resistance; hypothalamus-pituitary-adrenal axis;
sympathetic activity; visceral obesity
SYNDROME X IS CHARACTERIZED by a combination of insulin
resistance, impaired glucose tolerance, dyslipidemia,
sympathetic overactivity, and hypertension (42). It is
regarded as a major precursor for the development of
non-insulin-dependent diabetes mellitus (NIDDM).
There is a distinct relation between the symptoms of
syndrome X and weight maintenance. Weight gain
decreases insulin sensitivity and glucose tolerance and
increases blood pressure, whereas loss of excessive
weight normalizes these symptoms (38, 43, 45, 48, 50).
Epidemiological studies show that upper body obesity
is associated with a higher incidence of the symptoms
of syndrome X than is lower body obesity (4, 22, 32, 49).
This is primarily related to the amount of visceral fat
rather than to the amount of subcutaneous fat (2–4).
Visceral adipose tissue has metabolic characteristics
that are unique in comparison with other adipose tis-
sues. This is most pronounced for the regions that
drain on the portal vein, i.e., the omental and mesen-
teric adipose tissues. The fat cells from these regions
have increased b3-adrenoceptor sensitivity (24) and
higher lipolytic activity (28) than other adipocytes.
Increased lipolysis in these regions will expose the
liver directly to an exaggerated supply of long-chain
fatty acids.
Grekin and coworkers (20, 21) recently provided ev-
idence for reﬂex activation of the sympathoadrenal
system and hypothalamus-pituitary-adrenal axis
(HPA axis) in rats by increased supply of long-chain
fatty acids to the liver. This activation was associated
with an increase in heart rate (HR) and blood pressure.
In obesity, increased HPA axis activity and sympa-
thetic activity are associated with insulin resistance
(12, 26, 27), raising the possibility that reﬂex activa-
tion of the HPA axis and sympathoadrenal system
resulting from excess portal venous supply of long-
chain fatty acids plays a role in the induction of vis-
ceral obesity-related insulin resistance.
It was the aim of the present study to evaluate the
impact of the basic observations by Grekin and col-
leagues (20, 21) concerning the pathophysiological sig-
niﬁcance of portal venous supply of long-chain free
fatty acids (FFAs) to the liver. Speciﬁcally, we aimed to
investigate whether reﬂex activation of the HPA axis
and sympathetic system by an excessive portal venous
supply of long-chain fatty acids to the liver plays a role
in the development of insulin resistance. First, central
venous plasma norepinephrine (NE) and epinephrine
(Epi) levels, as indexes of sympathoadrenal activity,
and mean arterial blood pressure (MAP) and HR fre-
quency were determined during a 2-h intraportal infu-
sion of the long-chain fatty acid oleate. Infusion of the
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 medium-chain fatty acid caprylate or the solvent,
slightly alkaline saline, served as a control. In a second
set of experiments, rats received a portal venous infu-
sion of oleate, caprylate, or saline for 24 h. Before the
start of the infusion and in the 24th hour of infusion,
central venous plasma NE, Epi, and corticosterone
(Cort) concentrations were determined to assess sym-
pathoadrenal and HPA axis activity. Additionally, in
the 24th hour of infusion, insulin sensitivity was as-
sessed by means of an intravenous glucose tolerance
test (IVGTT). In a third series of experiments, hepatic
triglyceride (TG) production was measured to check for
alterations in hepatic lipid metabolism.
MATERIAL AND METHODS
Animal Care and Surgery
Male Wistar rats weighing 400–475 g at the beginning of
the studies were used. They were housed individually in
Plexiglas cages (25 3 25 3 30 cm; length 3 width 3 height)
at room temperature (21 6 2°C). The animals were main-
tained on a 12:12-h light-dark cycle (0700–1900 light) and
were handled and weighed every morning at 0900.
The animals were provided with silicon catheters through
one (experiments 1 and 3) or both (experiment 2) jugular veins
according to Steffens (51), with the tip of the catheters
positioned at the entrance of the right atrium. The other end
was externalized on top of the skull, where the ends were
ﬁxed with acrylic cement. This method allows frequent sam-
pling of well-mixed central venous blood from unanesthe-
tized, undisturbed, freely moving rats (52). Additionally, the
animals were provided with a silicon catheter in the portal
vein for intraportal infusion (54). Surgery was performed
under ether anesthesia.
For the experiments concerning the determination of blood
pressure and HR responses (experiment 1), the animals were
implanted with a blood pressure transmitter (TA 11PA-C40;
Dataquest), which, in combination with a receiver and a data
acquisition system, allows continuous registration of blood
pressure and HR. The tip of the blood transmitter was in-
serted in the descending aorta, and the body of the blood
pressure transmitter was positioned in the abdominal cavity.
The experiments started when the animals had regained
their preoperative body weight, but at least 10 days of recovery
aftersurgerywereallowed.Toavoidnoveltystress,theratshad
been accustomed to blood sampling procedures and experimen-
tal conditions before the ﬁrst actual experiment (8, 47).
All procedures were approved by the animal welfare com-
mittee of the University of Groningen.
Experimental Protocols
Experiment 1: Hemodynamic and sympathoadrenal effects
of intraportal fatty acid infusion. On the day of an experi-
ment, food was removed 3 h before the start of intraportal
infusion. At the same time, polyethylene tubing (length 400
mm, 1.25 mm ID, 1.75 mm OD) was connected to the outlets
of the catheters at the top of the skull of the animal. After 2 h,
when the animals were calm and resting, either blood sam-
pling or blood pressure and HR registration were started.
The animals received the infusions at a rate of 1.2 ml/h.
Sodium oleate (Sigma, St. Louis, MO) and sodium caprylate
(Sigma), dissolved in slightly alkaline saline, were infused at
a rate of 250 nmol/min (20, 21). The infusion solutions were
protected from light by wrapping the infusion syringes and
tubing. The solutions remained clear throughout the experi-
ments. Blood samples were withdrawn at time (t) 5 215, 21,
30, 60, 90, 120, 150, and 180 min relative to the start of the
infusion at t 5 0. The infusion was terminated after sampling
at t 5 120 min. Blood pressure and HR were registered for 30
min before the start of the infusion, during infusion, and for
60 min after the infusion was terminated.
The animals received the intraportal oleate, caprylate, or
saline infusion or the jugular vein oleate infusion in a ran-
dom order, with at least 4 days between consecutive experi-
ments. The experiments were performed between 1100 and
1700, i.e., in the light period. All animals participated in
multiple experiments.
Experiment 2: Effects of intraportal fatty acid infusion on
insulin sensitivity. Polyethylene tubing (length 400 mm, 1.25
mm ID, 1.75 mm OD) was connected to the outlets of the
catheters at the top of the animal’s skull. Two baseline
samples were withdrawn when the animals were calm and
resting, usually 1–1.5 h after connection of the sample lines.
Thereafter, the animals were connected to an infusion pump
for intraportal infusion of either sodium oleate (150 nmol/
min), sodium caprylate (150 nmol/min), or the solvent (saline;
1.2 ml/h). In the 24th hour of infusion, two baseline samples
were taken again (t 5 215 and 21 min). At t 5 0, an
intravenous glucose infusion (16 mg/min for 20 min) was
started for an IVGTT. Blood samples were withdrawn at t 5
5, 10, 15, and 20 min. The infusion was terminated after
sampling at t 5 20 min, and additional blood samples were
taken at t 5 25, 30, 35, and 40 min. All of the IVGTTs were
performed between 1200 and 1400, i.e., in the light period.
After the IVGTT, two to three animals per group were killed
for histological examination of the liver. For this purpose, parts
of the livers were ﬁxed by immersion in 4% phosphate-buffered
formalin and embedded in parafﬁn. Sections were stained with
hematoxylin-eosin for routine histology.
The animals that received an intraportal oleate infusion
had free access to food and water during the infusion period,
but food was taken away 2 h before the start of the IVGTT. To
control for feeding-related changes in nutritional status and
hormonal status and subsequently insulin sensitivity, the
animals that received either intraportal caprylate or saline
infusions were pair-fed (10 g/24 h) to the oleate-infused
group.
Experiment 3: Effects of oleate on hepatic TG production
rate. In the third experiment, hepatic TG production was
tested in either oleate- or caprylate-treated animals. To that
end, animals received an intravenous dose of Triton WR-1339
(12% wt/wt in saline, 0.5 ml/100 g body wt; Sigma) after 24 h
of intraportal infusion with either sodium oleate or sodium
caprylate (150 nmol/min at 1.2 ml/h). Triton WR-1339 is a
nonionic detergent that blocks lipoprotein lipase action, thus
preventing metabolism of lipoproteins, and traps lipoproteins
in the plasma. This allows the calculation of the hepatic very
low density lipoprotein (VLDL) TG production rate from the
linear increase in plasma TG concentration after intravenous
administration of the compound (17). Blood samples (300 ml)
were withdrawn at t 5 0, 1, 2, 3, 4, and 5 h relative to the
injection of Triton WR-1339.
Blood Sampling and Chemical Determinations
Blood samples were withdrawn for determination of glu-
cose in whole blood and for determination of Cort, Epi, NE,
immunoreactive insulin (IRI), FFA, cholesterol (Chol), TG,
alanine aminotransferase (ALT), alkaline phosphatase (AP),
and total bilirubin (tBi) in plasma. After each sample, an
equivoluminar amount of citrated (0.6% citrate) blood, ob-
tained from permanently cannulated donor rats, was rein-
E1287 PORTAL VENOUS LONG-CHAIN FATTY ACIDS AND SYNDROME X
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 fused. Between successive blood samples, the tip of the cath-
eter was ﬁlled with 6% citrate solution as an anticoagulant.
Citrate was used instead of heparin to avoid activation of
endothelial lipase.
After withdrawal, blood samples were transferred to
chilled (0°C) centrifuge tubes that contained 10 ml EDTA
solution (70 g/l) as anticoagulant and antioxidant. Glucose
was measured in 50 ml of blood by the ferricyanide method of
Hoffman (Technicon Auto Analyzer TM II). The remaining
blood was centrifuged for 15 min at 5,000 rpm at 4°C. One-
hundred microliters were stored at 270°C until handling for
catecholamine determination. Catecholamines were mea-
sured by HPLC with electrochemical detection (46). The
remaining plasma was stored at 220°C until handling for IRI
and Cort determination. IRI was determined by means of an
RIA (Linco). Plasma Cort was determined by means of re-
versed-phase HPLC with ultraviolet detection (11, 13).
Plasma FFA, Chol, TG, ALT, tBi, and AP concentrations
were measured by standard laboratory procedures.
Data Analysis and Statistics
Data are expressed as means 6 SE. Data for MAP and HR
are expressed as the mean changes over 15-min periods, taking
the values of period t 5 215–0 min before infusion as the
baseline. Within an experiment, Wilcoxon’s matched-pairs
signed rank test was used to compare the data obtained at each
moment relative to the baseline level. Two-way ANOVA with
repeated measures followed by the Mann-Whitney U-test was
used to determine differences between the experimental
groups. The level of signiﬁcance was set at P , 0.05.
RESULTS
Experiment 1
Table 1 summarizes the central venous plasma con-
centrations for NE and Epi and for MAP and HR
frequency as determined just before the start of intra-
portal fatty acid infusion. No signiﬁcant initial differ-
ences between the four conditions were observed.
Figure 1 presents the changes in central venous NE
and Epi concentrations as determined during 2 h of
fatty acid infusion. The results show a signiﬁcant in-
crease in central venous plasma NE and Epi concen-
trations during intraportal oleate infusion (NE: P ,
0.05 at t 5 60–180 min; Epi: P , 0.05 at t 5 90–180
min), whereas jugular vein infusion of oleate or intra-
portal infusion of caprylate or saline had no effect.
Figure 2 presents the changes in MAP and HR as
determined during intraportal fatty acid infusion. Both
MAP and HR showed a signiﬁcant increase during
intraportal oleate infusion (DMAP: P , 0.05 at t 5
22.5–172.5 min; DHR: P , 0.05 at t 5 37.5–172.5 min).
Fig. 2. Mean arterial pressure (MAP) and heart rate (HR) frequency
responses to 2 h of intraportal fatty acid infusion (250 nmol/min).
Data are expressed as average change (D 6 SE) from baseline, i.e.,
just before the start of infusion. *Signiﬁcant differences between the
experiment with oleate infusion and the experiments with caprylate
and saline infusion (P , 0.05). #Signiﬁcant increases in MAP and HR
in the experiment with jugular vein oleate infusion (P , 0.05).
Table 1. Baseline catecholamine, blood pressure,
and heart rate values for the experiments
with short-term fatty acid infusion
PA oleate
(n57)
PA caprylate
(n57)
PA saline
(n57)
Jug oleate
(n57)
NE, ng/l 142625 192645 210639 184636
Epi, ng/l 461 1469 19613 1064
MAP, mmHg 9764 9763 9863 10064
HR, beats/min 32668 331611 32766 32569
Values for norepinephrine (NE) and epinephrine (Epi) are aver-
ages 6 SE at time (t) 5 2 1 min, i.e., before the start of infusion.
Values for mean arterial pressure (MAP) and heart rate (HR) are
averages over a 15-min period before the start of infusion; n 5 7
animals in each group. PA, portal artery; Jug, jugular vein.
Fig. 1. Sympathoadrenal responses to 2 h of intraportal fatty acid
infusion (250 nmol/min). Data are expressed as average change (D 6
SE) from baseline, i.e., just before the start of infusion. D, Change; NE,
norepinephrine; Epi, epinephrine; pa, portal artery; jug, jugular vein.
*Signiﬁcant differences between the experiment with intraportal oleate
infusion and the experiments with caprylate or saline infusion (P , 0.05).
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 Infusion of oleate in the jugular vein induced signiﬁ-
cant increases in MAP and HR at t 5 22.5 min and at
t 5 7.5 and 22.5 min, respectively. Neither intraportal
caprylate nor saline affected MAP or HR.
Experiment 2
Table 2 summarizes the central venous blood glucose
concentrations and plasma concentrations for IRI,
FFA, TG, and Chol as determined just before the start
of the fatty acid infusion (pre) and in the 24th hour of
intraportal fatty acid infusion (post). No signiﬁcant
differences between the groups for glucose and IRI
were observed; both glucose and IRI slightly decreased
during the infusion period. FFA levels increased in all
three groups, whereas TG and Chol declined in oleate-
and caprylate-treated animals only (P , 0.05).
Figure 3 presents the changes in central venous
plasma concentration for Epi, NE, and Cort during
infusion. There were no signiﬁcant differences between
the groups at the onset of infusion. In the 24th hour of
intraportal infusion, both Cort and NE were signiﬁ-
cantly increased in the oleate-infused group compared
with the baseline and with the control groups. No
effects on Epi were observed.
Table 3 shows the central venous plasma concentra-
tions for ALT, AP, and tBi. There are no signiﬁcant
differences between the groups at the onset of the
infusion. Intraportal oleate infusion induced a signiﬁ-
cant increase in plasma ALT concentrations, whereas
caprylate and saline infusion had no effect. AP and tBi,
on the other hand, were not affected either by oleate,
caprylate, or saline infusion.
Figure 4 presents the mean changes from baseline at
t 5 21 min in blood glucose and plasma insulin con-
centrations during and after intravenous glucose infu-
sion. Intravenous infusion of glucose caused an in-
crease in blood glucose of 6.1 6 0.5, 6.7 6 0.7, and 5.1 6
0.5 mmol/l at t 5 20 min in oleate-, caprylate-, and
saline-treated animals, respectively. After termination
of glucose infusion, blood glucose declined to reach the
baseline at t 5 40 min in all three groups. There were
no signiﬁcant differences in the areas under the re-
sponse curves, i.e., 121 6 13, 135 6 20, and 95 6 11 for
the oleate-, the caprylate-, and the solvent-treated an-
imals, respectively. At the end of the infusion period,
i.e., at t 5 20 min, IRI had increased with 13.6 6 1.9
ng/ml in the oleate-treated animals. After termination
of glucose infusion, plasma IRI declined again to reach
the baseline at t 5 40 min. In the caprylate- and
solvent-treated groups, IRI showed an increase of only
6.6 6 0.9 and 6.4 6 0.7 ng/ml, respectively, above the
baseline at t 5 20 min (P , 0.05 compared with oleate).
After termination of glucose infusion, IRI declined to
reach the baseline at t 5 35 min in both control groups.
Calculated areas under the IRI response curves were
220 6 35 (P , 0.05), 112 6 13, and 106 6 8 for the
oleate-, caprylate-, and solvent-treated groups, respec-
tively.
Livers of animals killed after the IVGTT did not
show gross histological abnormalities or signs of in-
ﬂammation.
Table 2. Effects of intraportal fatty acid infusion on glucose, hormone, and lipid concentrations
Oleate (n 5 9) Caprylate (n 5 9) Saline (n 5 11)
Pre Post Pre Post Pre Post
Glucose, mmol/l 5.960.3 5.160.2 6.760.2 5.860.2 6.160.1 5.660.1
IRI, mg/l 3.160.5 1.760.1 3.060.3 1.360.2 3.36.3 1.760.2
FFA, mmol/l 0.2460.07 0.4960.05* 0.2160.03 0.3660.03 0.1860.02 0.4860.04
D FFA, mmol/l 10.2560.08 10.1560.05 10.3060.04
TG, mmol/l 0.8660.16 0.4860.07 1.2361.06 1.0660.11 0.6960.10 1.1660.21
D TG, mmol/l 20.3860.14 20.1760.16 0.5060.13†
Chol, mmol/l 1.6260.23 0.6960.11 2.1460.20 1.2160.08 2.0460.1 2.0760.04
D Chol, mmol/l 20.9360.32 20.9360.13 0.0460.09†
Values are means 6 SE; n, no. of rats. Pre, blood sample taken at t 5 2 1 min before start of infusion; post, blood sample taken in 24th
hour of intraportal infusion; IRI, immunoreactive insulin; FFA, free fatty acids; TG, triglycerides, Chol, cholesterol, all measured in central
venous plasma samples. D, difference in parameter value from pre to post. *P , 0.05, oleate vs. caprylate and saline. †P , 0.05, saline vs.
oleate and caprylate.
Fig. 3. Plasma corticosterone (Cort), NE, and Epi concentrations as
determined at the onset and in the 24th h of intraportal fatty acid
infusion (150 nmol/min). Data are expressed as averages 6 SE.
*Signiﬁcant differences between groups (P , 0.05).
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 Experiment 3
Figure 5 shows the accumulation of TGs in plasma
after intravenous Triton WR-1339 administration. In
the oleate-treated animals, total plasma TG concentra-
tion increased from 0.6 6 0.21 to 3.9 6 0.4 mmol/l over
the 5-h period after Triton WR-1339 administration. In
the caprylate-treated group, total plasma TG concen-
tration increased from 1.0 6 0.2 to 12.9 6 0.5 mmol/l in
the 5 h after Triton administration. The hepatic VLDL
TG production rates calculated from these curves were
11.0 6 1.2 and 36.8 6 2.9 mmol/h for oleate- and
caprylate-treated animals, respectively (P , 0.05). The
latter value is similar to our control values in un-
treated Wistar rats (44.8 6 6.9 mmol/h, n 5 3) and
representative data from the literature (17).
DISCUSSION
This study was designed to investigate whether ex-
cessive supply of long-chain fatty acids to the liver
could play a role in the induction of the metabolic
syndrome X. We hypothesized an increased portal ve-
nous supply of long-chain fatty acids to the liver to
induce reﬂex activation of the HPA axis and the sym-
pathetic system, leading to increased blood pressure
and the development of insulin resistance, both major
characteristic symptoms of syndrome X. Intraportal
infusion of the long-chain fatty acid oleate for 2 h at a
rate of 250 nmol/min caused an increase in resting
central venous plasma NE and Epi concentrations,
indicating increased resting sympathoadrenal activity.
MAP and HR frequency showed concomitant increases
during oleate infusion. The medium-chain fatty acid
caprylate and the solvent saline had no effect on either
sympathoadrenal activity or hemodynamic parame-
ters. Jugular vein infusion of oleate at an equimolar
rate did not induce signiﬁcant effects, indicating that
the effects on sympathetic activation and consequently
MAP and HR are speciﬁc for portal venous infusion.
These results conﬁrm earlier observations by Grekin
and coworkers (20, 21). These investigators showed
that the increase in MAP could be abolished by pre-
treatment with an a-adrenoceptor antagonist, indicat-
ing that sympathoadrenergically mediated vasocon-
striction, besides sympathoadrenergic stimulation of
HR frequency, is likely to play part in the increase in
MAP (20).
The experiments with long-term oleate infusion
showed signiﬁcantly increased NE and Cort concentra-
tions during the 24th hour of infusion, indicating that
the sympathetic system and HPA axis were activated.
In the series with oleate infusion, a signiﬁcantly in-
creased IRI response to intravenous glucose infusion
Fig. 5. Effect of intravenous Triton WR-1339 injection on plasma
triglyceride (TG) concentrations in rats that had received an intra-
portal infusion of either oleate (n 5 5) or caprylate (n 5 5) for 24 h.
Data are expressed as averages 6 SE. *Signiﬁcant differences be-
tween the groups (P , 0.05).
Table 3. Effects of intraportal fatty acid infusion on liver function parameters
Oleate Caprylate Saline
Pre Post Pre Post Pre Post
ALT, U/l 4562 2776102* 4763 4662 4362 4062
AP, U/l ,11 ,11 ,11 ,11 ,11 ,11
tBi, mmol/l 5.360.8 5.360.3 5.860.8 4.860.8 7.060.8 5.860.6
Values are means 6 SE. ALT, alanine aminotransferase; AP, alkaline phosphatase; tBi, total bilirubin; all measured in central venous
plasma samples. *P , 0.05, oleate vs. caprylate and saline.
Fig. 4. Plasma immunoreactive insulin (IRI) and blood glucose pro-
ﬁles to the intravenous glucose tolerance tests during intraportal
fatty acid infusion. Data are expressed as average change (D 6 SE)
from baseline, i.e., just before the start of infusion. *Signiﬁcant
differences between groups (P , 0.05).
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 was observed compared with caprylate or the solvent,
whereas the glucose response did not differ between
groups. Despite this increased IRI response in the
oleate-treated group, there was no difference in glucose
disappearance when the glucose infusion was termi-
nated. These observations clearly indicate that intra-
portal oleate infusion did induce insulin resistance,
whereas intraportal caprylate infusion did not. This
induction of insulin resistance was independent of the
feeding state of the animals, since the control groups
were pair-fed to the oleate-treated animals. These ﬁnd-
ings are consistent with our proposed concept concern-
ing the induction of visceral obesity-related insulin
resistance.
Obesity-related insulin resistance has been sug-
gested to result from hyperinsulinemia as a conse-
quence of reduced insulin uptake by the liver, caused
by overexposure of the liver to FFAs (30, 39). However,
in vitro and in vivo studies by Boden and coworkers (6,
7, 29) have failed to support this concept. Alternatively,
it has been hypothesized that FFAs induce insulin
resistance, either directly or indirectly, and thereby
provoke a compensatory increase in insulin secretion
(5). The results of the present study support this con-
cept, since insulin resistance did develop in oleate-
treated rats, despite decreasing baseline IRI concen-
trations. The latter is probably due to the feeding
condition of the animals, because semistarvation (;10
g/24 h), with subsequently decreased blood glucose
concentrations, induced a lowering of IRI in all three
groups.
The results therefore strongly support a role for the
HPA axis and sympathetic activation in mediating the
oleate-induced development of insulin resistance. In-
creased HPA axis activity has been reported to be a
potent mediator of insulin resistance (26, 27). Humans
(44) as well as animals (57) treated with glucocorticoids
develop insulin resistance. Moreover, insulin resis-
tance is commonly observed in people suffering from
Cushing’s syndrome (36). Corticosteroids have been
suggested to induce insulin resistance via an increase
in circulating FFAs. However, dexamethasone-induced
impairment in skeletal muscle glucose transport is not
reversed by inhibition of FFA oxidation (58), indicating
that corticosteroids may have a direct effect on insulin
sensitivity. This is conﬁrmed in an animal model for
high-fat feeding-induced insulin resistance in skeletal
muscle, where treatment with the antiglucocorticoid
RU-486 resulted in an amelioration of insulin resis-
tance (31). As such, this ﬁnding is consistent with the
hypothesis that HPA axis hyperreactivity may be in-
volved in the development of obesity-related insulin
resistance. In addition to increased HPA axis activity,
increased sympathetic activity, as seen with oleate
infusion, may also act as a causal factor in the devel-
opment of insulin resistance (12, 15, 26, 41).
We do observe an increase in HPA axis activity, as
reﬂected by a signiﬁcant increase in plasma Cort, and
sympathetic activity, as reﬂected by an increase in
plasma NE, after 24 h of intraportal oleate infusion.
Although these increases are rather acute, they are
consistent with the increase in HPA axis and sympa-
thetic activity observed in obesity (1, 26, 55, 56). The
origin of this increased HPA axis and sympathetic
activity is still unclear. Reﬂex activation originating
from the liver is a possible source. There is abundant
evidence from animal studies that afferent sympa-
thetic and parasympathetic nerves from the liver are
responsive to metabolic changes in hepatic cells (19,
34). In a study directly relevant to the basic hypothesis
of this study, Orbach and Andrews (37) reported in-
creases in vagal afferent activity after infusion of the
long-chain fatty acid palmitate into the hepatic artery
of rabbits, whereas infusion of short-chain fatty acids
had no effect.
Hepatic vagal afferent activity in obesity could orig-
inate from changes in hepatic functioning. Intraportal
infusion of oleate, caprylate, or the solvent saline did
not lead to increases in either AP or tBi, indicating that
the animals were not hampered by cholestasis. If the
oleate infusion had had detergent-like properties, then
hemolysis would have occurred and tBi would have
increased. We did not observe any increase in tBi, thus
excluding hemolysis. We did observe moderate in-
creases in plasma ALT, a marker for hepatic leakage,
after 24 h of intraportal oleate infusion. This increase
in plasma ALT could be seen as a marker for hepatic
steatosis; however, no changes in morphology were
observed in parafﬁn-embedded liver coupes. We there-
fore conclude that the unspeciﬁc detergent-like proper-
ties of the fatty acid solutions that we infused were
minimal at the most. Alternatively, the increase in
ALT can very well be due to oleate-induced activation
of hepatic peroxisome proliferator-activated receptor
(PPAR)-a. In Hep G2 cells, PPARa stimulation with
fenoﬁbrate induces markedly increased ALT-mRNA
levels (14). Long-chain fatty acids are, like fenoﬁbrate,
potent stimulants for PPARa, indicating that transam-
inase activity can be altered independently of a toxic
phenomenon (14).
Although the increase in circulating hepatic en-
zymes that we observe is rather acute, it is remarkable
that analog increases of serum transaminase activity
have been documented in obese patients (16, 23, 25,
35). The increases in serum transaminase activity in
obesity can be observed before overt fatty liver or
steatosis. It is therefore unclear whether increased
transaminase activity results from fatty liver or steato-
sis or whether these symptoms have one common
source. In the present case, hepatic transaminase leak-
age could be an early symptom of obesity-induced al-
terations in hepatic functioning, leading to fat deposi-
tion and ultimately steatosis.
Increased serum transaminase activity has been as-
sociated with symptoms of syndrome X. Hollmann et
al. (25) showed a strong correlation between the waist-
to-hip ratio and plasma ALT concentrations and other
characteristics of syndrome X. Fagerberg et al. (16)
reported a signiﬁcant correlation of ALT to plasma
insulin, independent of body mass index. Moreover,
Perry et al. (40) observed a strong, graded, and inde-
pendent association between the concentration of
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 g-glutamyltransferase in serum and the risk of
NIDDM during long-term follow-up. Based on these
observations and on the results obtained in the present
study, we advocate the hypothesis that excessive portal
venous supply of long-chain fatty acids alters hepatic
functioning, resulting in increased transaminase activ-
ity. This altered hepatic functioning is recognized by
the central nervous system and results in HPA axis
and sympathetic activation, leading to the symptoms of
syndrome X. It may therefore serve as the causal factor
in the development of syndrome X. It could be the
“common soil” that has been referred to in the perspec-
tive of the development of syndrome X and NIDDM
(53).
It is surprising that oleate infusion at a rate of only
150 nmol/min has the signiﬁcant effects that are ob-
served. Grekin et al. (21) calculated that exogenous
infusion of oleate at a rate of 250 nmol/min (experiment
1) increased hepatic oleate delivery only by 12% and
total fatty acid delivery by 2%. When extrapolated, this
would give increases in hepatic oleate and total fatty
acid delivery of only 7 and 1.2%, respectively, for an
infusion rate of 150 nmol/min (experiment 2) based on
values for the postabsorptive state. In the postprandial
state, plasma FFA concentrations may decrease by
80–90%, meaning that an infusion rate of 150 nmol/
min could have increased hepatic oleate delivery by as
much as 100%. After oleate infusion for 24 h, the actual
plasma FFA concentration had doubled from 0.24 6
0.07 to 0.49 6 0.05 mmol/l. This increase, however,
cannot be responsible for the observed effects, since the
control groups showed comparable increases in total
plasma FFA due to the feeding conditions of the ani-
mals and the related decrease in plasma IRI. It may be
that the observed effects are due to speciﬁc effects of
increased supply of unbound long-chain, rather then
medium-chain, FFAs to the liver (21), which is esti-
mated to be increased about three times during infu-
sion of oleate at a rate of 150 nmol/min.
Intraportal oleate infusion resulted in decreased he-
patic TG secretion compared with caprylate infusion.
At ﬁrst sight, this result seems rather paradoxical. In
vitro studies have shown that long-chain fatty acids
stimulate hepatic VLDL production (e.g., Ref. 33).
Moreover, corticosteroids, which signiﬁcantly in-
creased in the experiments with oleate infusion, are
potent stimulators of hepatic VLDL production in vivo
(10). On the contrary, a-adrenoceptor stimulation is
known to decrease VLDL production (9). NE, a potent
stimulator of a-adrenoceptors, is signiﬁcantly in-
creased after intraportal oleate infusion. Therefore, it
seems likely that an NE-induced, a-adrenoceptor-me-
diated decrease of VLDL production overrules a poten-
tial corticosteroid-mediated stimulation of VLDL TG
production, leading to a net decrease in VLDL produc-
tion. Because insulin resistance and NIDDM are char-
acterized by increased VLDL production (18), it is
likely that the decreased VLDL TG production reﬂects
the acute nature of this experiment and, in fact, is a
transient phenomenon. In any case, the results of the
present study emphasize the strong metabolic actions
of portal oleate supply to the liver.
Taken together, the results from the present study in
part conﬁrm the data presented by Grekin and col-
leagues (20, 21). Moreover, the results show that an
increase in portal venous supply of long-chain fatty
acids to the liver induces HPA axis and sympathetic
activation with concomitant development of increased
MAP and insulin resistance. These metabolic actions of
portal venous fatty acids might contribute to the etiol-
ogy of obesity-related insulin resistance. These ﬁnd-
ings expand the original hypothesis for the induction of
obesity-related hypertension to the development of
obesity-related insulin resistance and probably syn-
drome X.
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